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Abstract 
Purpose: Concurrent chemoradiation (CCRT) is the standard curative treatment of anal canal cancer (ACC). The 
role of a brachytherapy (BRT) boost in this setting is still debated. Therefore, the aim of this analysis was to retrospec-
tively evaluate the clinical outcomes in a large cohort of ACC patients treated with CCRT plus BRT boost or external 
beam radiotherapy (EBRT) boost. 
Material and methods: Patients with non-metastatic ACC, treated in our department between January 2003 and 
December 2014 were included in this analysis. The initial treatment was based on EBRT to the pelvis (prescribed dose, 
45 Gy/1.8 Gy) plus concurrent chemotherapy (5-fluorouracil and mitomycin-C). Patients received a pulsed-dose-rate 
BRT boost on the primary tumor (median dose, 20 Gy; range, 13-25 Gy) 2-3 weeks after the end of CCRT. In patients with 
contraindications to BRT, an EBRT boost (prescribed dose, 16 Gy, 2 Gy/fraction) was delivered immediately after CCRT. 
Results: One-hundred-twenty-three patients were included in this analysis (median age, 61 years; range, 36-93 
years; squamous-cell carcinoma, 78%; HIV+, 6%; median follow-up, 71 months; range, 2-158 months). The actuarial 
5-year local control (LC), distant metastasis-free survival, colostomy-free survival, and overall survival (OS) rates were 
81.7%, 92.3%, 62.3%, and 74.0%, respectively. At univariate analysis, patients aged ≤ 65 years (p < 0.010), cT1-2 stage 
(p = 0.004), and receiving a BRT boost (p = 0.015) showed significantly improved OS. At multivariate analysis, ad-
vanced tumor stage cT3-cT4 (HR, 2.12; 95% CI: 1.09-4.14; p = 0.027), and age > 65 years (HR, 3.03; 95% CI: 1.54-5.95; 
p = 0.001) significantly predicted increased risk of mortality. The crude rate of toxicity-related colostomies was 4.9%.
Conclusions: The role of BRT boost in ACC remains unclear since the outcomes were not clearly different com-
pared to CCRT alone. However, further improvement of clinical results in ACC treatment is needed, and therefore 
prospective trials based on advanced (image-guided/adapted) BRT techniques are warranted. 
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Purpose 
Anal canal cancer (ACC) is a relatively rare malig-
nancy representing about 0.4% of all new diagnosed neo-
plasm [1], with an age-adjusted incidence ratio of 0.32 per 
100,000 in the US [2]. Over the past decades, perhaps due 
to increased transmission of HIV and HPV, the incidence 
has increased without clear improvement in survival even 
if distant metastases occur in only 5-10% of cases [3,4]. 
Concurrent chemoradiation (CCRT) based on exter-
nal beam radiation therapy (EBRT) plus concurrent 5-flu-
orouracil (5-FU) and mitomycin-C (MMC) represents 
the standard treatment option in non-metastatic ACC 
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according to results reported from several randomized 
trials [5,6,7,8]. However, 20% and 30% 5-year rates of 
local-regional recurrences and colostomy, respectively, 
have been reported after CCRT [8,9]. 
Brachytherapy (BRT) boost has been used to improve 
these outcomes by delivering a higher and more focused 
dose to the primary tumor. However, no robust evidence 
is available on the real advantage produced by a BRT 
boost after CCRT [10]. Furthermore, most published se-
ries were based on the use of low-dose-rate (LDR) BRT 
and data on the efficacy of pulsed-dose-rate (PDR) are 
lacking. PDR is a theoretically advantageous BRT tech-
nique, since it combines the radiobiological advantages of 
LDR BRT with the dosimetrical advantages of high-dose-
rate BRT. 
Therefore, the aim of this study was to contribute 
to the current evidence on this issue by retrospectively 
reviewing a large series of patients with prolonged fol-
low-up, treated with CCRT followed by PDR BRT boost. 
Material and methods 
Study design and objectives 
This was a monocentric retrospective analysis of fea-
sibility and clinical outcomes of CCRT followed by BRT 
boost in ACC. The study was approved by our institu-
tional review board. Patients ≥ 18 years with histologi-
cally proven non-metastatic ACC with any tumor (T) and 
nodal (N) stage, treated with CCRT followed by a BRT 
boost (or EBRT boost if BRT was contraindicated) were 
eligible for inclusion. Patients with distant metastases or 
locally recurrent disease and with tumors of the anal mar-
gin were excluded. 
From January 2003 to December 2014, 185 patients with 
ACC were treated in our department. Among them, 123 
patients were selected according to our inclusion criteria.
 
Staging and treatment 
Clinical stage was defined according to the American 
Joint Committee on Cancer criteria [11] by digital rectal 
examination, anorectal ultrasonography, proctoscopy, 
computed tomography (CT) scan, and magnetic reso-
nance imaging (MRI). 18F-FDG-PET-CT imaging was 
used only in a few selected patients with doubtful results 
after the standard exams. 
Patients were first treated with pelvic CCRT. Con-
current continuous infusion of 5-FU (1,000 mg/m2/day 
continuous intravenous infusion for 4 consecutive days in 
the first and fourth week of EBRT treatment) and MMC 
(10 mg/m2/day bolus intravenous infusion on day 1 and 
29 of EBRT treatment) were administered. Pelvic EBRT 
started on the first day of chemotherapy (CHT). The 
prescribed dose was 45 Gy (1.8 Gy/fraction). EBRT was 
planned with 3-dimensional conformal technique using 
3 or 4 fields and delivered with a linear accelerator (6-18 MV 
photon energy) with the patient in prone position. The 
clinical target volume (CTV) was defined as the gross tu-
mor volume (GTV), the anal canal and the whole mesorec-
tum, internal and external iliac nodes, obturator nodes, 
and presacral nodes. The GTV extension was evaluated in 
all patients by transrectal ultrasound. Inguinal nodes were 
included in the CTV only if metastatic and in patients with 
cT3-4 ACC or with positive pelvic nodes, according to the 
Radiation Therapy Oncology Group guidelines. The dose 
was prescribed and specified according to the Internation-
al Commission on Radiation Units Measurements report 
no 50 (ICRU 50) [12]. 
In 53 patients with positive nodes at clinical staging, 
a sequential boost was delivered to the involved lymph 
nodes using multiple fields technique (6-18 MV photons; 
median dose, 18 Gy; range, 14-20 Gy; 2 Gy/fraction) or 
with a direct electron beam (20 Gy in 2 Gy/fraction) in 
case of inguinal nodes. 
Clinical response evaluation was performed at the 
end of CCRT by clinical examination. Patients with can-
cer involving > 2/3 of the anal canal circumference or 
with > 1 cm involvement of perianal skin before CCRT, 
or with residual disease > 5 cm in longitudinal or > 1.5 cm 
in circumferential direction after CCRT, or with medical 
contraindication to anesthesia were considered not eli-
gible for BRT and were treated with EBRT boost. EBRT 
boost was delivered immediately after CCRT with mul-
tiple fields technique (16 Gy, 1.8 Gy/fraction). The BRT 
boost was delivered 2-3 weeks after CCRT to allow recov-
ery from acute toxicity using 192Ir sources. The needles of 
an active length varying from 5 to 8 cm depending on the 
size of the tumor were positioned in parallel, with a dis-
tance of 1 cm interval to ensure adequate dosimetry using 
a perineal template under general anesthesia. To locate 
the residual tumor or scar, 1-2 landmarks of silver were 
inserted. At the end of the implantation prior to insertion 
of the 192Ir sources, all patients underwent two orthogo-
nal radiograms in order to verify the correct alignment 
and position of the hollow needles. In case of deviations 
detectable with this method, the same needles were re-
positioned. Dose was prescribed and specified based on 
the Paris system [13] and delivered with 0.67-0.8 Gy/
hour PDR, lasting 24-36 hours. In case of residual disease 
after CCRT, a BRT boost dose ≥ 20 Gy was prescribed. If 
complete clinical response was observed after CCRT, the 
BRT dose was ≤ 16 Gy. Furthermore, for T1-2 and T3-4, the 
median number of charged loaded needles were 5 and 
6-7, respectively. 
Follow-up 
Follow-up visits were performed by a multidisci-
plinary team including clinical examination and anorec-
tal ultrasonography every 4 months in the first two years 
after treatment, every 6 months in the following 3 years, 
and then yearly. Biopsies under anesthesia were used 
for differential diagnosis between recurrence and radia-
tion-induced complications, but never before 6 months 
from the end of the treatment due to the risk of complica-
tions and the low probability of early local relapse. 
Statistical analysis 
Local control (LC), colostomy-free survival (CFS), 
distant metastatic-free survival (DMFS), and overall sur-
vival (OS) were calculated from the date the treatment 
started. LC was evaluated considering events clinical-
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ly evident for local-regional (T and N) disease relapse, 
persistence, or progression, positive biopsy, and salvage 
surgery. DMFS was evaluated taking into consideration 
any treatment failure outside the pelvis. OS was defined 
as death resulting from any cause. Colostomy-free sur-
vival was measured from the day of treatment initiation 
to colostomy, death, or last follow-up evaluation if the 
patient was alive with no surgery. Descriptive statistics 
was used to report patient, tumor, and treatment charac-
teristics. Survival functions were described using the Ka-
plan-Meier method [14] and compared with log-rank test 
[15] to investigate differences in OS, LC, CFS, and DMFS 
between groups defined, based on clinical and patholog-
ical factors. Multivariable analysis was performed using 
Cox’s proportional hazard model [16]. Covariates to be 
introduced in the multivariable models were selected 
based on backward stepwise strategy (p inclusion < 0.1; 
p exclusion ≥ 0.1). All tests were two-sided and p value 
< 0.05 was considered statistically significant. Statistical 
analysis was performed with SPSS version 22.0 (IBM 
Corp., Armonk, NY, USA). 
Results 
From 123 ACC patients included in this analysis, 116 
were treated with CCRT followed by a sequential boost of 
BRT (102 patients) or EBRT (21 patients), while 7 patients 
did not receive CT because of advanced age (> 85 years, 
3 patients), cardiovascular comorbidities (3 patients), and 
severe herpes zoster infection (1 patient). The median 
prescribed BRT boost dose was 20 Gy (range, 13-25 Gy). 
Median follow-up was 71 months (range, 2-158 months). 
Patients characteristic are summarized in Table 1. 
Two-, 5-, and 10-year OS rates were 88.6%, 74.0%, 
and 64.3%, respectively (Figure 1). At univariate anal-
ysis, age ≤ 65 years (p < 0.010), initial tumor stage T1-2 
(p = 0.004), and sequential boost delivered with BRT 
(p = 0.015) were significantly correlated with improved 
OS (Table 2). At multivariable analysis, patients with cT3-4 
stage (HR, 2.12; 95% CI: 1.09-4.14; p = 0.027) and aged 
> 65 years (HR, 3.03; 95% CI: 1.54-5.95; p = 0.001) showed 
a significantly higher risk of mortality. Table 3 shows 
LC, CFS, and DMFS stratified for clinical-pathologi-
cal factor at univariate analysis. Twenty-two patients 
had local recurrence, more frequently in male patients 
(p < 0.001). Two-, 5-, and 10-year LC was 84.2%, 81.7%, 
and 81.7%, respectively (Figure 2). Considering the large 
and statistically significant difference in terms of LC be-
tween gender, a detailed analysis of this difference in 
various tumor stage subgroups was performed (Table 
4). Our analysis showed that a statistically higher LC 
rate in female patients was recorded in T1-2N0 subjects 
(p < 0.001) with a trend in the T1-2N+ and in the T3-4N+ 
groups (p = 0.085 and p = 0.082, respectively). Ten patients 
developed metastases, and 2-, 5-, and 10-year DMFS 
was 93.3%, 92.3%, and 92.3%, respectively (Figure 3). 
DMFS rate was higher in patients treated with BRT boost 
(p < 0.001). Two-, 5-, and 10-year CFS was 74.8%, 62.3%, 
and 55.2%, respectively (Figure 4). CFS was significant-
ly worse in male patients (p < 0.001) and in patients 
> 65 years old (p = 0.002). Overall, 26 patients underwent 
colostomy during follow-up (21.1%). In 20 patients, colos-
tomy was performed because of local recurrence (16.3%) 
and in 6 cases because of treatment-related toxicity 
(4.9%). Colostomy due to treatment-related toxicity was 
recorded in 5 patients treated with BRT boost (4.9%) and 
in 1 patient treated with EBRT boost (4.8%). 
Table 1. Patient characteristics of the analyzed 
cohort with the number of patients’ and percen-
tage of the total number of patients [%]
Variable Median (range) No. of patients (%) 
Age (years) 61 (36-93)
Follow-up (months) 71 (2-158)
Gender
Male 30 (24.4)
Female 93 (75.6)
Age (years)
≤ 65 71 (57.7)
> 65 52 (42.3)
Histology 
Squamous 96 (78.0)
Cloacogenic 8 (6.5)
Basaloid 14 (11.4)
Other 5 (4.1)
cT-stage 
1 18 (14.6)
2 45 (36.6)
3 41 (33.3)
4 19 (15.4)
cN-stage 
N0 70 (56.9)
N1 28 (22.8)
N2 13 (10.5)
N3 12 (9.8)
HIV 
Positive 7 (5.7)
Negative 116 (94.3)
BRT – brachytherapy, EBRT – radiotherapy, HIV – human immunodeficiency 
virus, No – number Fig. 1. Overall survival
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Table 2. Univariate analysis including 2- and 5-year overall survival, median survival time, and log-rank  
p-value 
Variable No. of patients 2-year OS (%) 5-year OS (%) Median OS (months) p value 
Gender
Male 30 86.7 62.2 NR 0.096 
Female 93 89.2 79.0 158 
Age (years)
≤ 65 71 93.0 84.1 NR < 0.001 
> 65 52 82.7 62.3 119 
Histology 
Squamous 96 87.5 74.4 158 0.556 
Cloacogenic 8 87.5 46.7 57 
Basaloid 14 92.9 85.7 NR 
Other 5 100.0 80.0 NR 
HIV
Positive 7 85.7 85.7 NR 0.489 
Negative 116 88.8 74.4 158 
cT-stage
T1 18 100.0 88.2 NR 0.020 
T2 45 95.6 81.8 NR 
T3 41 75.6 63.1 158 
T4 19 89.5 66.3 NR 
cT-stage
T1-2 63 96.8 83.6 NR 0.004 
T3-4 60 80.0 63.9 158 
cN-stage
N0 70 90.0 79.5 NR 0.235 
N1 28 96.4 73.1 78 
N2 13 69.2 61.5 158 
N3 12 83.3 66.7 95 
cN-stage 
N0 70 90.0 77.9 NR 0.058 
N1-N2-N3 53 86.8 68.9 109 
Boost
Brachytherapy 102 91.2 78.7 158 0.015 
External beam RT 21 76.2 51.6 NR 
BRT boost dose (Gy)
≤ 18 38 97.4 84.0 158 0.284 
> 18 64 87.5 75.8 NR 
Chemotherapy
No 7 85.7 42.9 43 0.059 
Yes 116 88.8 75.9 158 
BRT – brachytherapy, HIV – human immunodeficiency virus, No – number, NR – not reached, OS – overall survival, RT – radiotherapy 
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Table 3. Univariate analysis including 2- and 5-year colostomy-free survival, local control, metastasis-free 
survival, and log-rank p-value 
Variable No. of 
patients 
2-year 
CFS (%) 
5-year 
CFS (%) 
p value 2-year 
LC (%) 
5-year 
LC (%) 
p value 2-year 
DMFS (%) 
5-year 
DMFS (%) 
p value
Gender
Male 30 56.7 32.7 < 0.001 69.0 56.4 < 0.001 96.2 96.2 0.361 
Female 93 80.6 71.8 91.0 89.8 92.4 91.1 
Age (years)
≤ 65 71 81.7 71.8 0.002 86.8 83.7 0.400 94.3 92.7 0.779 
> 65 52 63.5 48.9 81.9 78.8 91.9 91.9 
Histology
Squamous 96 76.0 62.1 0.532 85.9 82.2 0.832 92.5 91.2 0.782 
Cloacogenic 8 50.0 50.0 71.4 71.4 100.0 100.0 
Basaloid 14 78.6 78.6 84.6 84.6 92.9 92.9 
Other 5 80.0 60.0 80.0 80.0 100.0 100.0 
HIV
Positive 7 75.0 62.6 0.717 71.4 57.1 0.078 100.0 100.0 0.453 
Negative 116 71.4 57.1 85.5 83.4 92.0 91.8 
cT-stage
T1-2 63 81.0 64.0 0.006 85.7 84.0 0.445 95.2 93.4 0.564 
T3-4 60 68.3 49.2 83.2 78.9 91.3 91.3 
cN-stage
N0 70 72.9 67.1 0.189 84.2 84.2 0.830 94.2 94.2 0.387 
N1-2-3 53 77.4 55.9 85.4 78.4 92.1 89.6 
Boost
BRT 102 77.5 65.4 0.198 86.1 83.9 0.215 95.0 95.0 0.015 
EBRT 21 61.9 47.6 75.6 68.0 81.7 77.0 
BRT boost dosage (Gy)
≤ 18 38 86.8 73.5 0.335 92.1 92.1 0.233 100.0 100.0 0.050 
> 18 64 82.3 80.5 91.9 91.9 
Chemotherapy
No 7 71.9 60.7 0.186 100.0 100.0 0.242 100.0 100.0 0.443 
Yes 116 85.7 42.9 83.7 80.7 92.9 91.8 
BRT – brachytherapy, CFS – colostomy-free survival, DMFS – distant metastatic-free survival, EBRT – external beam radiotherapy, HIV – human immunodeficiency 
virus, LC – local control, No – number, NR – not reached 
Discussion 
In this retrospective analysis on 123 patients with 
ACC treated with CCRT followed by PDR BRT boost, the 
5-year rates of LC, CFS, and OS were 81.7%, 62.3%, and 
74.0%, respectively. Furthermore, the 10-year rates of LC, 
CFS, and OS were 81.7%, 55.2%, and 64.3%, respectively. 
Moreover, we recorded a crude rate of 4.9% of patients 
receiving colostomy due to treatment-related toxicity. 
The study suffers from several limitations: retro-
spective design, no available data on acute toxicity, no 
separate analysis of local and regional relapses, lack of 
description of late toxicity apart from those requiring co-
lostomy, and lack of information about number and site 
of metastatic nodes. 
However, this analysis presents one of the largest 
available series and the longest follow-up period. Fur-
thermore, to the best of our knowledge, it is the largest 
series on PDR-based BRT boost in ACC. 
Comparing our results with the ones of other series 
using LDR BRT boost after CCRT [10], the clinical results 
seem to be quite similar. In particular, in this current 
study and the series analyzed by Frakulli et al., 5-year LC 
was 81.7% vs. 78.6%, CFS was 62.3% vs. 76.1%, and OS 
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was 74.0% vs. 69.4%. However, it should be noted that 
our patients had a more unfavorable prognostic profile 
compared to those included in the review by Frakulli 
et al. (cT1-2: 51.2% vs. 61.0%; cN0: 56.9% vs. 72.3%, SCC 
histology: 78.0% vs. 94.2%). Our crude rate of toxicity-re-
lated colostomies was similar to the one presented in the 
above-mentioned review (4.9% vs. 3.7%). In conclusion, 
based on this data, we cannot draw definitive conclu-
sions about the PDR BRT advantage as boost technique 
after CCRT. 
We also tried to compare our results with those of 5-FU 
plus MMC arm of the RTOG-9811 randomized trial, where 
a CCRT dose of 45-59 Gy without BRT boost was prescribed 
[8,9]. Again, the clinical results of our series are similar to 
those reported in that trial. In particular, in our analysis and 
in the RTOG-9811 study, 5-year LC was 81.7% vs. 80.0%, 
CFS was 62.3% vs. 71.9%, and OS was 74.0% vs. 78.3%. Even 
in this case, the comparison is complicated by the different 
prognostic profile of our series and that of the RTOG trial 
(cT1-2: 51.2% vs. 63.0%; cN0: 56.9% vs. 70.0%, SCC histology: 
78.0% vs. 86.0%). However, the finding of similar results in 
an unfavorable prognostic population would lead to the hy-
pothesis of some benefit in patients undergoing BRT boost. 
A comparison of our treatment-related colostomy rate 
(4.9%) with that of the RTOG trial is complicated because 
this data was not clearly reported in the two publications 
[8,9]. The authors only stated that the rate of late grade 4 gas-
trointestinal complications was 3% without describing the 
side effects types. However, if we compare the 5-year LC 
(80.0%) with the 5-year CFS (71.9%) recorded in the RTOG 
trial [8,9], we can hypothesize that the rate of colostomies 
due to toxicity was not negligible and probably almost sim-
ilar to the one recorded in our series. 
In the last 5 years, some studies on the use of IMRT-SIB 
in this setting have been published [17,18,19,20,21]. The 
use of IMRT is promising, since a reduction in acute toxic-
ity has been demonstrated with the use of this technique. 
Furthermore, the use of IMRT-SIB allows the delivery of 
an increased total dose and dose per fraction on the mac-
roscopic tumor. Therefore, this technique is potentially 
useful to intensify the effect of CCRT as an alternative to 
BRT boost. However, the efficacy of IMRT-SIB is hardly 
comparable with our case series, since all publications re-
ported results with a shorter timing (< 5 years). The only 
data that can be observed even with this modern tech-
nique is the reported rate of around 4% of treatment-re-
lated colostomies due to toxic effects [20,21]. 
In our series, we observed (as expected in a tumor 
with relatively favorable prognosis) a worse OS in older 
Fig. 2. Local control
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Fig. 3. Distant metastasis-free survival
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Fig. 4. Colostomy-free survival
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Table 4. Univariate analysis comparing local control in male and female patients in different tumor stage 
subgroups
Stage Number of patients 2-year local control 5-year local control p value
Male Female Male Female Male Female 
T1-2 N0 12 35 58.3 97.1 58.3 97.1 < 0.001 
T1-2 N1-2-3 3 13 66.7 84.6 33.3 84.6 0.085 
T3-4 N0 7 16 71.4 80.8 71.4 80.8 0.649 
T3-4 N1-2-3 8 29 71.4 92.3 57.1 88.1 0.082 
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patients. Furthermore, significantly higher DMFS and OS 
rates were recorded at univariate analysis in patients un-
dergoing BRT boost compared to EBRT boost. This result 
could be attributed to a probably larger tumor volume 
in patients treated with EBRT technique, even if we can-
not confirm this hypothesis due to lack of data on tumor 
volume or simply tumor diameter. We also observed sig-
nificantly lower CFS rate in male patients as described by 
Franco et al. [17] and significantly lower LC in the same 
patients. A negative prognostic effect of male gender was 
previously reported also in the RTOG 9811 trial [9]. 
Another interesting result of our analysis is that 5-year 
and 10-year rates of LC and DMFS were identical. This 
data would suggest that late ACC relapses are very rare. 
Two groups reported the results of small series, pre-
senting very preliminary data on IGBT/IABT-based BRT 
boost in ACC [22,23]. In the first study, 11 patients under-
went CCRT followed by BRT boost (total EQD2, 60 Gy) that 
was planned with multi-parametric MRI. With 25 months 
median follow-up, Tagliaferri et al. reported 91% LC (crude 
rate), without cases of grade > 2 late toxicity [22]. Similarly, 
Kapoor et al. treated 16 patients with CT-based IGBT boost 
and reported 87.5% 2-year LC rate and no cases of grade 
> 2 late toxicity (median follow-up, 41 months) [23].
In conclusion, based on the retrospective design and 
other limitations of our analysis, we cannot recommend 
the routine prescription of a BRT boost in clinical practic-
es. However, there is a need for further improvement of 
the results of ACC treatment, where clinical outcomes did 
not change significantly in the last decades. Therefore, fur-
ther evaluation of this technique, with the aim to improve 
its efficacy and safety, is warranted. The use of IGBT tech-
niques in combination with IMRT-based irradiation of the 
pelvic and inguinal volumes should be tested in well-de-
signed prospective trials. In order to favor treatment mod-
ulation with tailored techniques and doses, it is necessary 
that future studies will describe in detail the results strat-
ifying them based on the characteristics of the neoplasm 
and particularly, in terms of stage and histology. 
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